uploads///syringe _

Analysts’ Recommendations for Akcea and Its Peers in March

By

Mar. 21 2018, Updated 3:25 p.m. ET

Company overview

Akcea Therapeutics (AKCA) is a late-stage biopharmaceutical company. Akcea Therapeutics is currently advancing a mature pipeline of four novel drugs with the potential to treat multiple cardiometabolic diseases. 

AKCA’s pipeline includes volanesorsen, AKCEA-APO, AKCEA-ANGPTL, and AKCEA-APOCIII, which are based on Ionis Pharmaceuticals’ (IONS) antisense technology.

Article continues below advertisement

Analysts’ recommendations

In March 2018, two of the four analysts covering Akcea Therapeutics have given the stock “buy” or higher ratings, while two have given it “hold” ratings. The mean rating for the stock is 2.25, and its target price is $30.

Peers’ ratings

Eleven of the 26 analysts covering Amgen (AMGN) have given the stock “buy” or higher ratings, and 15 analysts have given it “hold” ratings in March. The mean rating for the stock is 2.38, and its target price is $195.7.

Of the 21 analysts covering bluebird bio (BLUE) in March, 12 analysts have given the stock “buy” or higher ratings, eight have given it “hold” ratings, and one has given it a “sell” rating. The mean rating for the stock is 2.19, and its target price is $217.61.

Of the 14 analysts covering Ionis Pharmaceuticals in March, five analysts have given the stock “buy” or higher ratings. Seven analysts have given the stock “hold” ratings, and two analysts have given it “sell” or lower ratings. The mean rating for the stock is 2.79, and its target price is $57.

In the next part of the series, we’ll take a look at Akcea Therapeutics’ drug pipeline.

Advertisement

More From Market Realist